AI MARKET SCANNING

AN2 Therapeutics, Inc.

AVG HISTORICAL GAP -0.15%
MAX GAP RECORD -5.93%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ANTX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 11, 2026 Earnings Release 2026-08-11 (AFTER CLOSE)
+3.75%
May 11, 2026 Earnings Release 2026-05-11 (AFTER CLOSE)
-2.97%
Mar 17, 2026 Earnings Release 2026-03-17 (AFTER CLOSE)
-3.00%
Nov 12, 2025 Earnings Release 2025-11-12 (AFTER CLOSE)
-5.93%
Aug 12, 2025 Earnings Release 2025-08-12 (AFTER CLOSE)
+0.95%
May 13, 2025 Earnings Release 2025-05-13 (AFTER CLOSE)
-1.69%
Mar 25, 2025 Earnings Release 2025-03-25 (AFTER CLOSE)
-0.67%
Nov 13, 2024 Earnings Release 2024-11-13 (AFTER CLOSE)
+1.98%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.5%
Bullish Gaps (5)
Bearish Gaps (6)
Neutral / Flat (3)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ANTX

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗